Related Experiment Video
Updated: Feb 21, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
26.6K
Diabetes and Ramadan: A concise and practical update.
Mohamed H Ahmed1, Nazik Elmalaika Husain2, Wadie M Elmadhoun3
1Department of Medicine and HIV Metabolic Clinic, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keynes, Buckinghamshire, UK.
Journal of Family Medicine and Primary Care
|October 14, 2017
Summary
Many people with diabetes fast during Ramadan, with new drugs like vildagliptin and liraglutide showing safety. Sulfonylureas are less recommended due to hypoglycemia risks, while insulin use and education are also discussed for diabetes management during Ramadan.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Public Health
Background:
- Ramadan fasting involves prolonged daily fasting periods (12-16 hours) for 29-30 days.
- A significant number of individuals with diabetes observe fasting during Ramadan.
- Managing diabetes during Ramadan presents unique challenges due to altered eating patterns and fasting duration.
Purpose of the Study:
- To review the safety and efficacy of modern antidiabetic pharmacotherapies for individuals with diabetes fasting during Ramadan.
- To discuss the role of insulin therapy, new technologies, and patient education in Ramadan diabetes management.
- To identify areas requiring further research in Ramadan-focused diabetes care.
Main Methods:
- Literature review of recent pharmacological agents for diabetes management.
- Analysis of current guidelines regarding diabetes and Ramadan fasting.
- Inclusion of discussions on insulin therapy, insulin pumps, and educational strategies.
Main Results:
- Newer agents like vildagliptin, sitagliptin, and liraglutide are considered safe for use during Ramadan fasting.
- These agents can be safely combined with metformin.
- Sulfonylureas are generally not recommended due to an increased risk of hypoglycemia.
- Insulin therapy, insulin pumps, and pre-fasting education are important considerations.
Conclusions:
- Modern antidiabetic medications offer safer options for individuals with diabetes fasting during Ramadan.
- Careful consideration of medication choice, insulin use, and patient education is crucial for safe and effective diabetes management during Ramadan.
- Further research is warranted to fully understand the benefits of novel antidiabetic agents and technologies in this context.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
01:22Diabetes Mellitus: Type 2 and Gestational
5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.4K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.4K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.6K
01:20Pathophysiology of Diabetes
3.8K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.8K
01:16Insulin: Dosing Regimen and Adverse Effects
883
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
883